AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00591578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
Study NCT02882477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Study NCT00374205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate plus Amodiaquine
Description: Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
Study NCT02882477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin
Study NCT01097902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral one time only
Study NCT03018717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemonitoring Constant
Description: telemedicine of Constant
Study NCT03018717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard clinical care
Description: The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
Study NCT01097902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet oral one time only
Study NCT00518349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive bending function
Description: Colonoscope with a passive bending function
Study NCT04180709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepio
Description: Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
Study NCT00260650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart PACT Program
Description: patient activation intervention
Study NCT04181398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anthropometry
Description: * Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference.
Study NCT00518349 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No passive bending function
Description: Examination using standard colonoscope without passive bending function
Study NCT01883037 — intervention group
Intervention type: OTHER
Intervention: Blood glucose results
Description: The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
Study NCT04181398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
Study NCT02113293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol®
Description: Cyclosporine A Solution
Study NCT02113293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Vehicle Solution
Study NCT04181398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral arterial tonometry
Description: The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
Study NCT04181398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: General questionnaire on cardiovascular risk factors
Study NCT04181398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for hs-CRP
Study NCT01552434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT05251155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distant best corrected visual acuity assessment
Description: Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
Study NCT02081612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: 12 educational weight management group session each addressing a different weight loss topic
Study NCT02081612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 12 weight loss acupuncture session using both body and auricular points.
Study NCT00276848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine plus Cyclophosphamide
Description: fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
Study NCT00276848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
Study NCT03110120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Description: Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Study NCT03110120 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Description: local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
Study NCT03110120 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with physiological saline
Description: Serratus plane block realized with 20 ml of injectable solution of physiological saline
Study NCT04115722 — intervention group
Intervention type: OTHER
Intervention: IBD ACTIVIT
Description: Effect of IBD disease and activity of disease on coagulation parameters
Study NCT03110120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine injectable solution with physiological saline
Description: local infiltration of the wound with 20 ml of injectable solution of physiological saline
Study NCT00911235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single 8 mg oral dose of fesoterodine
Study NCT00911235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fesoterodine plus fluconazole
Description: On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
Study NCT00952913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 4 x 100-mg oral tablets, single dose
Study NCT00952913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 2 x 30-mg oral tablets, single daily doses for 2 days
Study NCT02788240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg GCSF
Study NCT02788240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Albumin
Study NCT02788240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20% Albumin
Study NCT02788240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Study NCT02788240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Study NCT02788240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel wash
Study NCT00696163 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
Study NCT02788240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel wash
Study NCT02788240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin 1- 4mg,if indicated
Study NCT02788240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin 1- 4mg,if indicated
Study NCT02788240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem or Imepenem, if indicated
Study NCT02788240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem or Imepenem, if indicated
Study NCT02788240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03611608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531
Description: Administered IV
Study NCT03611608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01310283 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: xylitol mints and fluoride varnish
Description: Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
Study NCT04225156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod
Description: Intravenous infusion of efgartigimod
Study NCT02342730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Specialist
Description: Referred to a weight loss specialist
Study NCT02342730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete EORTC-QLQ questionnaires
Study NCT02342730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Chart reviews are performed
Study NCT01142921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-reflux Tannenbaum biliary stent
Description: Anti-reflux Tannenbaum biliary stent
Study NCT01142921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary Tannenbaum biliary stent
Description: Ordinary Tannenbaum biliary stent
Study NCT01017315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baby talcum
Description: 50 grams apply locally prior cast application
Study NCT02750423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DHCA+RCP
Description: During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
Study NCT02750423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MHCA + SACP
Description: During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
Study NCT01416662 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine hydrochloride
Study NCT03454620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: GC1118 combination with irinotecan
Study NCT03454620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: GC1118 combination with FOLFIRI
Study NCT01552434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01552434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01552434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies
Study NCT01552434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02729233 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patients receiving biopsies
Description: Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
Study NCT00975923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Group
Description: In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams.
Study NCT00975923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tool Kit
Description: Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
Study NCT01307072 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Vitrectomy. Diabetic retinopathy
Study NCT02845804 — intervention group
Intervention type: DEVICE
Intervention: Alpine
Study NCT01887808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil DermaControl Oil Control Moisturizer SPF 30
Study NCT00889434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ECGC
Description: 1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
Study NCT00889434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol
Description: One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
Study NCT00889434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EGCG + Tocotrienol
Description: combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
Study NCT02460731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\] Solution for intravenous infusion
Study NCT01940588 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychoanalytic therapy
Description: Psychotherapy, medication management
Study NCT03325439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) intravenous (iv)
Description: Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment.
Study NCT01552434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Given PO
Study NCT03216629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Saying sorry
Description: The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?
Study NCT03325439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) oral
Description: Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
Study NCT01925794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF
Study NCT03301714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Education
Description: Group-based oral health education vs Individual-based oral health education using motivational interviewing
Study NCT03897621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ertugliflozin 5 mg
Description: Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
Study NCT02036515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.